Oral contraceptives may increase risk for developing gliomas
the ONA take:
According to a new study published in the British Journal of Clinical Pharmacology, researchers have found that certain forms of birth control may increase the risk for developing a glioma, a rare brain cancer.
For the study, researchers analyzed data from Denmark's national registries of health records, cancer cases, and prescriptions in order to identify women aged 15 to 49 years diagnosed with glioma and which women were prescribed contraceptives.
Results showed that women who had used hormonal contraceptives (estrogen, progestin, or both) had a 50% increased risk for developing gliomas compared with those who did not take hormonal contraceptives. In addition, women who used birth control for greater than 5 years had a nearly 200% increased risk for developing gliomas.
Women taking progestin-only contraceptives were at a slightly higher risk for developing the brain cancer than those who took estrogen only or both. The researchers note that although the risk is doubled, the cancer is still rare. Specifically, among Danish women aged 15 to 49 years, only five in 100,000 will develop a glioma.
The results of the study were surprising as previous studies have found that estrogen and progestin may decrease the risk of gliomas, but particularly in post-menopausal women.
Certain forms of birth control may increase the risk for developing a glioma, a rare brain cancer.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|